Tisagenlecleucel Moves to Earlier Lines of Therapy for Pediatric, Young Adults With ...
Tisagenlecleucel (Kymriah) is increasingly used in earlier lines of therapy for pediatric and young adult relapsed/refractory B-ALL, reducing HSCT use and high disease burden. Data from the CIBMTR registry show a decrease in late-line tisagenlecleucel use and high disease burden rates, with improved morphological CR rates and favorable long-term safety profiles.
Reference News
Tisagenlecleucel use in relapsed/refractory B-ALL reduced HSCT use and high disease burden, with improved outcomes and safety profiles across age groups, according to 2024 SOHO data.
Tisagenlecleucel (Kymriah) is increasingly used in earlier lines of therapy for pediatric and young adult relapsed/refractory B-ALL, reducing HSCT use and high disease burden. Data from the CIBMTR registry show a decrease in late-line tisagenlecleucel use and high disease burden rates, with improved morphological CR rates and favorable long-term safety profiles.